Corabotase Phase 2 Data Show Sustained Glabellar Line Improvement Through 24 Weeks

Ipsen's first-in-class recombinant neuroinhibitor corabotase has demonstrated sustained duration of effect and high patient satisfaction in glabellar lines through 24 weeks, according to phase 2 data presented on May 16, 2026, at the Scale Symposium in Nashville, Tennessee.1

The LANTIC trial results showed that 60.8% of patients treated with corabotase maintained clinically significant improvement at Week 24, compared with 36.7% for Dysport (abobotulinumtoxinA) and .2% for placebo. The findings come as Ipsen advances corabotase into phase 3 development, with the 50-ng dose selected for further evaluation in the company's LAURITE program.1

"First data are encouraging for patients, based on the overall satisfaction results, and I look forward to following the corabotase journey," said Martina Kerscher, MD, professor of dermatology and head of cosmetic sciences at the University of Hamburg, who presented the data at the symposium.

What the phase 2 LANTIC Trial Showed in Glabellar Lines

The data presented at Scale represent proof-of-concept results from stage 1 of the LANTIC trial, a phase 1/2 study enrolling 727 patients across three aesthetic indications involving moderate-to-severe upper facial lines. The glabellar lines cohort included 183 patients evaluated in a dose-finding and dose-escalation design with corabotase, Dysport, and placebo arms.

At Week 4, 66% of patients treated with corabotase 50 ng achieved a 2-grade or greater composite improvement in glabellar line severity, compared with 0% for placebo (P = .0001), meeting the study’s primary endpoint. In the Dysport arm, 54.3% achieved the same threshold at week 4.1

The durability signal was notable: at week 24, 60.8% of corabotase-treated patients maintained an investigator-assessed score of "none" or "mild" for line severity, compared with 36.7% for Dysport and 0.2% for placebo. Patient-reported data demonstrated a rapid onset of action, with a mean time to effect of .84 days. Patient satisfaction at Week 24 was reported at 82.8%, based on "very satisfied" or "satisfied" ratings on the Subject Level of Satisfaction 4-point categorical scale. Additionally, corabotase continued to show a greater response in line severity compared with Dysport at week 36.1

"We are pleased to share that these data demonstrated many firsts for the aesthetics industry," Christelle Huguet, PhD, executive vice president and head of research and development at Ipsen, said in a statement.1

Safety Profile and Drug Mechanism of Corabotase

Corabotase was well-tolerated across the evaluated doses, with no significant safety concerns reported in stage 1. The frequency of adverse events (AEs) was comparable across all treatment arms, including corabotase, Dysport, and placebo.1

Corabotase (IPN10200) is a purposefully engineered recombinant neuroinhibitor distinguished from conventional botulinum toxins by its synthetic construction. Unlike naturally derived botulinum neurotoxins, corabotase is built from engineered functional domains, a catalytic A domain and a binding B domain, optimized through advanced protein engineering to increase receptor affinity, enhance cellular uptake, and improve resistance to degradation.

References

1. Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction. May 16, 2026. Accessed May 18, 2026. https://www.ipsen.com/press-release/ipsen-presents-first-in-class-late-breaking-phase-ii-corabotase-data-in-glabellar-lines-showing-sustained-duration-of-effect-reinforced-by-consistently-high-patient-satisfaction-3296217/.